Global Contrast Agents

Contrast Agents Comprehensive Study by Type (Iodine-based, Barium-Sulfate, Gadolinium), Application (Interventional Radiology, Interventional Cardiology), Route of Administration (Intravenously/intra-arterially, Orally, Rectally), End-User (Hospital & Clinics, Ambulatory Surgery Centers, Diagnostic Imaging Centers), Modality (X-Rays, Computed Tomography (CT), Magnetic Resonance (MR) Imaging, Ultrasound) Players and Region - Global Market Outlook to 2026

Contrast Agents Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Contrast Agents Market Scope
Contrast materials, also known as contrast agents or contrast media, are used to improve x-ray, computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound images of the inside of the body. Contrast materials are frequently used to help the radiologist distinguish between normal and pathological situations. Contrast materials are not dyes that stain internal organs permanently. They are compounds that alter the way x-rays and other imaging instruments interact with the body for a short period of time. Contrast materials, when injected into the body before an imaging exam, cause particular structures or tissues in the body to appear differently on the images than they would if no contrast material had been injected. Contrast materials help distinguish or contrast selected areas of the body from surrounding tissue. By improving the visibility of specific organs, blood vessels or tissues, contrast materials help physicians diagnose medical conditions.

The Contrast Agents market study is segmented by Type (Iodine-based, Barium-Sulfate and Gadolinium), by Application (Interventional Radiology and Interventional Cardiology) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansion and acquisition to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Asia Pacific Players will contribute to the maximum growth of Global Contrast Agents market throughout the predicted period.

E Healthcare (United States), Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging, Inc. (United States), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals Ltd. (India), SANOCHEMIA Pharmazeutika GmbH (Austria), Taejoon Pharm (South Korea), Jodas Expoim (India), Nano Therapeutics Pvt. Ltd. (India), Kiran X-ray (India), iMax Diagnostic Imaging Limited (Ireland) and K DIAM EXIM (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Congruent Pharmachem Private Limited (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China) and Subhra Pharma Pvt. Ltd. (India).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Contrast Agents market by Type, Application and Region.

On the basis of geography, the market of Contrast Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In 2020, GE Healthcare Pharma Limited acquired the ownership of Daiichi Sankyo’s four diagnostic agents in Japan.
In Feb. 22, 2021 - Bracco Announces U.S. FDA Approval of 20-Vial Configuration of LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use. LUMASON is an ultrasound contrast agent indicated for use: in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms, in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients, and in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients and In 2020, Bracco Imaging SpA received approval from the US FDA for its product ProHance, which is an MRI contrast agent for use in neonates and pediatric patients under two years of age.


Market Trend
  • Increasing Volume of CT and MRI Examinations Performed

Market Drivers
  • Increasing Prevalence of Chronic Diseases
  • Rising Approvals of Contrast Agents

Opportunities
  • Increasing Research on Contrast Agents
  • Rising Number of Diagnostic Centers and Hospitals

Restraints
  • Side-effects and Allergic Reactions Associated with Contrast Agents

Challenges
  • Technological Advancements in Imaging Solutions
  • Restriction and Withdrawal of Linear Gadolinium-based Contrast Agents


Key Target Audience
Manufacturers of Contrast Agent, Suppliers of Contrast Agent, Wholesalers, Distributors and Retailers of Contrast Agent, Healthcare Industry, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Iodine-based
  • Barium-Sulfate
  • Gadolinium
By Application
  • Interventional Radiology
  • Interventional Cardiology
By Route of Administration
  • Intravenously/intra-arterially
  • Orally
  • Rectally

By End-User
  • Hospital & Clinics
  • Ambulatory Surgery Centers
  • Diagnostic Imaging Centers

By Modality
  • X-Rays
  • Computed Tomography (CT)
  • Magnetic Resonance (MR) Imaging
  • Ultrasound

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Chronic Diseases
      • 3.2.2. Rising Approvals of Contrast Agents
    • 3.3. Market Challenges
      • 3.3.1. Technological Advancements in Imaging Solutions
      • 3.3.2. Restriction and Withdrawal of Linear Gadolinium-based Contrast Agents
    • 3.4. Market Trends
      • 3.4.1. Increasing Volume of CT and MRI Examinations Performed
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Contrast Agents, by Type, Application, Route of Administration, End-User, Modality and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Contrast Agents (Value)
      • 5.2.1. Global Contrast Agents by: Type (Value)
        • 5.2.1.1. Iodine-based
        • 5.2.1.2. Barium-Sulfate
        • 5.2.1.3. Gadolinium
      • 5.2.2. Global Contrast Agents by: Application (Value)
        • 5.2.2.1. Interventional Radiology
        • 5.2.2.2. Interventional Cardiology
      • 5.2.3. Global Contrast Agents by: Route of Administration (Value)
        • 5.2.3.1. Intravenously/intra-arterially
        • 5.2.3.2. Orally
        • 5.2.3.3. Rectally
      • 5.2.4. Global Contrast Agents by: End-User (Value)
        • 5.2.4.1. Hospital & Clinics
        • 5.2.4.2. Ambulatory Surgery Centers
        • 5.2.4.3. Diagnostic Imaging Centers
      • 5.2.5. Global Contrast Agents by: Modality (Value)
        • 5.2.5.1. X-Rays
        • 5.2.5.2. Computed Tomography (CT)
        • 5.2.5.3. Magnetic Resonance (MR) Imaging
        • 5.2.5.4. Ultrasound
      • 5.2.6. Global Contrast Agents Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Contrast Agents (Price)
      • 5.3.1. Global Contrast Agents by: Type (Price)
  • 6. Contrast Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. E Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bracco Imaging SPA (Italy)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Guerbet (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lantheus Medical Imaging, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Unijules Life Sciences (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. J.B. Chemicals and Pharmaceuticals Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. SANOCHEMIA Pharmazeutika GmbH (Austria)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Taejoon Pharm (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Jodas Expoim (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Nano Therapeutics Pvt. Ltd. (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Kiran X-ray (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. IMax Diagnostic Imaging Limited (Ireland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. K DIAM EXIM (India)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Contrast Agents Sale, by Type, Application, Route of Administration, End-User, Modality and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Contrast Agents (Value)
      • 7.2.1. Global Contrast Agents by: Type (Value)
        • 7.2.1.1. Iodine-based
        • 7.2.1.2. Barium-Sulfate
        • 7.2.1.3. Gadolinium
      • 7.2.2. Global Contrast Agents by: Application (Value)
        • 7.2.2.1. Interventional Radiology
        • 7.2.2.2. Interventional Cardiology
      • 7.2.3. Global Contrast Agents by: Route of Administration (Value)
        • 7.2.3.1. Intravenously/intra-arterially
        • 7.2.3.2. Orally
        • 7.2.3.3. Rectally
      • 7.2.4. Global Contrast Agents by: End-User (Value)
        • 7.2.4.1. Hospital & Clinics
        • 7.2.4.2. Ambulatory Surgery Centers
        • 7.2.4.3. Diagnostic Imaging Centers
      • 7.2.5. Global Contrast Agents by: Modality (Value)
        • 7.2.5.1. X-Rays
        • 7.2.5.2. Computed Tomography (CT)
        • 7.2.5.3. Magnetic Resonance (MR) Imaging
        • 7.2.5.4. Ultrasound
      • 7.2.6. Global Contrast Agents Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Contrast Agents (Price)
      • 7.3.1. Global Contrast Agents by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Contrast Agents: by Type(USD Million)
  • Table 2. Contrast Agents Iodine-based , by Region USD Million (2015-2020)
  • Table 3. Contrast Agents Barium-Sulfate , by Region USD Million (2015-2020)
  • Table 4. Contrast Agents Gadolinium , by Region USD Million (2015-2020)
  • Table 5. Contrast Agents: by Application(USD Million)
  • Table 6. Contrast Agents Interventional Radiology , by Region USD Million (2015-2020)
  • Table 7. Contrast Agents Interventional Cardiology , by Region USD Million (2015-2020)
  • Table 8. Contrast Agents: by Route of Administration(USD Million)
  • Table 9. Contrast Agents Intravenously/intra-arterially , by Region USD Million (2015-2020)
  • Table 10. Contrast Agents Orally , by Region USD Million (2015-2020)
  • Table 11. Contrast Agents Rectally , by Region USD Million (2015-2020)
  • Table 12. Contrast Agents: by End-User(USD Million)
  • Table 13. Contrast Agents Hospital & Clinics , by Region USD Million (2015-2020)
  • Table 14. Contrast Agents Ambulatory Surgery Centers , by Region USD Million (2015-2020)
  • Table 15. Contrast Agents Diagnostic Imaging Centers , by Region USD Million (2015-2020)
  • Table 16. Contrast Agents: by Modality(USD Million)
  • Table 17. Contrast Agents X-Rays , by Region USD Million (2015-2020)
  • Table 18. Contrast Agents Computed Tomography (CT) , by Region USD Million (2015-2020)
  • Table 19. Contrast Agents Magnetic Resonance (MR) Imaging , by Region USD Million (2015-2020)
  • Table 20. Contrast Agents Ultrasound , by Region USD Million (2015-2020)
  • Table 21. South America Contrast Agents, by Country USD Million (2015-2020)
  • Table 22. South America Contrast Agents, by Type USD Million (2015-2020)
  • Table 23. South America Contrast Agents, by Application USD Million (2015-2020)
  • Table 24. South America Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 25. South America Contrast Agents, by End-User USD Million (2015-2020)
  • Table 26. South America Contrast Agents, by Modality USD Million (2015-2020)
  • Table 27. Brazil Contrast Agents, by Type USD Million (2015-2020)
  • Table 28. Brazil Contrast Agents, by Application USD Million (2015-2020)
  • Table 29. Brazil Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 30. Brazil Contrast Agents, by End-User USD Million (2015-2020)
  • Table 31. Brazil Contrast Agents, by Modality USD Million (2015-2020)
  • Table 32. Argentina Contrast Agents, by Type USD Million (2015-2020)
  • Table 33. Argentina Contrast Agents, by Application USD Million (2015-2020)
  • Table 34. Argentina Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 35. Argentina Contrast Agents, by End-User USD Million (2015-2020)
  • Table 36. Argentina Contrast Agents, by Modality USD Million (2015-2020)
  • Table 37. Rest of South America Contrast Agents, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Contrast Agents, by Application USD Million (2015-2020)
  • Table 39. Rest of South America Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 40. Rest of South America Contrast Agents, by End-User USD Million (2015-2020)
  • Table 41. Rest of South America Contrast Agents, by Modality USD Million (2015-2020)
  • Table 42. Asia Pacific Contrast Agents, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Contrast Agents, by Type USD Million (2015-2020)
  • Table 44. Asia Pacific Contrast Agents, by Application USD Million (2015-2020)
  • Table 45. Asia Pacific Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 46. Asia Pacific Contrast Agents, by End-User USD Million (2015-2020)
  • Table 47. Asia Pacific Contrast Agents, by Modality USD Million (2015-2020)
  • Table 48. China Contrast Agents, by Type USD Million (2015-2020)
  • Table 49. China Contrast Agents, by Application USD Million (2015-2020)
  • Table 50. China Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 51. China Contrast Agents, by End-User USD Million (2015-2020)
  • Table 52. China Contrast Agents, by Modality USD Million (2015-2020)
  • Table 53. Japan Contrast Agents, by Type USD Million (2015-2020)
  • Table 54. Japan Contrast Agents, by Application USD Million (2015-2020)
  • Table 55. Japan Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 56. Japan Contrast Agents, by End-User USD Million (2015-2020)
  • Table 57. Japan Contrast Agents, by Modality USD Million (2015-2020)
  • Table 58. India Contrast Agents, by Type USD Million (2015-2020)
  • Table 59. India Contrast Agents, by Application USD Million (2015-2020)
  • Table 60. India Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 61. India Contrast Agents, by End-User USD Million (2015-2020)
  • Table 62. India Contrast Agents, by Modality USD Million (2015-2020)
  • Table 63. South Korea Contrast Agents, by Type USD Million (2015-2020)
  • Table 64. South Korea Contrast Agents, by Application USD Million (2015-2020)
  • Table 65. South Korea Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 66. South Korea Contrast Agents, by End-User USD Million (2015-2020)
  • Table 67. South Korea Contrast Agents, by Modality USD Million (2015-2020)
  • Table 68. Taiwan Contrast Agents, by Type USD Million (2015-2020)
  • Table 69. Taiwan Contrast Agents, by Application USD Million (2015-2020)
  • Table 70. Taiwan Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 71. Taiwan Contrast Agents, by End-User USD Million (2015-2020)
  • Table 72. Taiwan Contrast Agents, by Modality USD Million (2015-2020)
  • Table 73. Australia Contrast Agents, by Type USD Million (2015-2020)
  • Table 74. Australia Contrast Agents, by Application USD Million (2015-2020)
  • Table 75. Australia Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 76. Australia Contrast Agents, by End-User USD Million (2015-2020)
  • Table 77. Australia Contrast Agents, by Modality USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Contrast Agents, by Type USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Contrast Agents, by Application USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Contrast Agents, by End-User USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Contrast Agents, by Modality USD Million (2015-2020)
  • Table 83. Europe Contrast Agents, by Country USD Million (2015-2020)
  • Table 84. Europe Contrast Agents, by Type USD Million (2015-2020)
  • Table 85. Europe Contrast Agents, by Application USD Million (2015-2020)
  • Table 86. Europe Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 87. Europe Contrast Agents, by End-User USD Million (2015-2020)
  • Table 88. Europe Contrast Agents, by Modality USD Million (2015-2020)
  • Table 89. Germany Contrast Agents, by Type USD Million (2015-2020)
  • Table 90. Germany Contrast Agents, by Application USD Million (2015-2020)
  • Table 91. Germany Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 92. Germany Contrast Agents, by End-User USD Million (2015-2020)
  • Table 93. Germany Contrast Agents, by Modality USD Million (2015-2020)
  • Table 94. France Contrast Agents, by Type USD Million (2015-2020)
  • Table 95. France Contrast Agents, by Application USD Million (2015-2020)
  • Table 96. France Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 97. France Contrast Agents, by End-User USD Million (2015-2020)
  • Table 98. France Contrast Agents, by Modality USD Million (2015-2020)
  • Table 99. Italy Contrast Agents, by Type USD Million (2015-2020)
  • Table 100. Italy Contrast Agents, by Application USD Million (2015-2020)
  • Table 101. Italy Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 102. Italy Contrast Agents, by End-User USD Million (2015-2020)
  • Table 103. Italy Contrast Agents, by Modality USD Million (2015-2020)
  • Table 104. United Kingdom Contrast Agents, by Type USD Million (2015-2020)
  • Table 105. United Kingdom Contrast Agents, by Application USD Million (2015-2020)
  • Table 106. United Kingdom Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 107. United Kingdom Contrast Agents, by End-User USD Million (2015-2020)
  • Table 108. United Kingdom Contrast Agents, by Modality USD Million (2015-2020)
  • Table 109. Netherlands Contrast Agents, by Type USD Million (2015-2020)
  • Table 110. Netherlands Contrast Agents, by Application USD Million (2015-2020)
  • Table 111. Netherlands Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 112. Netherlands Contrast Agents, by End-User USD Million (2015-2020)
  • Table 113. Netherlands Contrast Agents, by Modality USD Million (2015-2020)
  • Table 114. Rest of Europe Contrast Agents, by Type USD Million (2015-2020)
  • Table 115. Rest of Europe Contrast Agents, by Application USD Million (2015-2020)
  • Table 116. Rest of Europe Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 117. Rest of Europe Contrast Agents, by End-User USD Million (2015-2020)
  • Table 118. Rest of Europe Contrast Agents, by Modality USD Million (2015-2020)
  • Table 119. MEA Contrast Agents, by Country USD Million (2015-2020)
  • Table 120. MEA Contrast Agents, by Type USD Million (2015-2020)
  • Table 121. MEA Contrast Agents, by Application USD Million (2015-2020)
  • Table 122. MEA Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 123. MEA Contrast Agents, by End-User USD Million (2015-2020)
  • Table 124. MEA Contrast Agents, by Modality USD Million (2015-2020)
  • Table 125. Middle East Contrast Agents, by Type USD Million (2015-2020)
  • Table 126. Middle East Contrast Agents, by Application USD Million (2015-2020)
  • Table 127. Middle East Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 128. Middle East Contrast Agents, by End-User USD Million (2015-2020)
  • Table 129. Middle East Contrast Agents, by Modality USD Million (2015-2020)
  • Table 130. Africa Contrast Agents, by Type USD Million (2015-2020)
  • Table 131. Africa Contrast Agents, by Application USD Million (2015-2020)
  • Table 132. Africa Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 133. Africa Contrast Agents, by End-User USD Million (2015-2020)
  • Table 134. Africa Contrast Agents, by Modality USD Million (2015-2020)
  • Table 135. North America Contrast Agents, by Country USD Million (2015-2020)
  • Table 136. North America Contrast Agents, by Type USD Million (2015-2020)
  • Table 137. North America Contrast Agents, by Application USD Million (2015-2020)
  • Table 138. North America Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 139. North America Contrast Agents, by End-User USD Million (2015-2020)
  • Table 140. North America Contrast Agents, by Modality USD Million (2015-2020)
  • Table 141. United States Contrast Agents, by Type USD Million (2015-2020)
  • Table 142. United States Contrast Agents, by Application USD Million (2015-2020)
  • Table 143. United States Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 144. United States Contrast Agents, by End-User USD Million (2015-2020)
  • Table 145. United States Contrast Agents, by Modality USD Million (2015-2020)
  • Table 146. Canada Contrast Agents, by Type USD Million (2015-2020)
  • Table 147. Canada Contrast Agents, by Application USD Million (2015-2020)
  • Table 148. Canada Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 149. Canada Contrast Agents, by End-User USD Million (2015-2020)
  • Table 150. Canada Contrast Agents, by Modality USD Million (2015-2020)
  • Table 151. Mexico Contrast Agents, by Type USD Million (2015-2020)
  • Table 152. Mexico Contrast Agents, by Application USD Million (2015-2020)
  • Table 153. Mexico Contrast Agents, by Route of Administration USD Million (2015-2020)
  • Table 154. Mexico Contrast Agents, by End-User USD Million (2015-2020)
  • Table 155. Mexico Contrast Agents, by Modality USD Million (2015-2020)
  • Table 156. Contrast Agents: by Type(USD/Units)
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Contrast Agents: by Type(USD Million)
  • Table 172. Contrast Agents Iodine-based , by Region USD Million (2021-2026)
  • Table 173. Contrast Agents Barium-Sulfate , by Region USD Million (2021-2026)
  • Table 174. Contrast Agents Gadolinium , by Region USD Million (2021-2026)
  • Table 175. Contrast Agents: by Application(USD Million)
  • Table 176. Contrast Agents Interventional Radiology , by Region USD Million (2021-2026)
  • Table 177. Contrast Agents Interventional Cardiology , by Region USD Million (2021-2026)
  • Table 178. Contrast Agents: by Route of Administration(USD Million)
  • Table 179. Contrast Agents Intravenously/intra-arterially , by Region USD Million (2021-2026)
  • Table 180. Contrast Agents Orally , by Region USD Million (2021-2026)
  • Table 181. Contrast Agents Rectally , by Region USD Million (2021-2026)
  • Table 182. Contrast Agents: by End-User(USD Million)
  • Table 183. Contrast Agents Hospital & Clinics , by Region USD Million (2021-2026)
  • Table 184. Contrast Agents Ambulatory Surgery Centers , by Region USD Million (2021-2026)
  • Table 185. Contrast Agents Diagnostic Imaging Centers , by Region USD Million (2021-2026)
  • Table 186. Contrast Agents: by Modality(USD Million)
  • Table 187. Contrast Agents X-Rays , by Region USD Million (2021-2026)
  • Table 188. Contrast Agents Computed Tomography (CT) , by Region USD Million (2021-2026)
  • Table 189. Contrast Agents Magnetic Resonance (MR) Imaging , by Region USD Million (2021-2026)
  • Table 190. Contrast Agents Ultrasound , by Region USD Million (2021-2026)
  • Table 191. South America Contrast Agents, by Country USD Million (2021-2026)
  • Table 192. South America Contrast Agents, by Type USD Million (2021-2026)
  • Table 193. South America Contrast Agents, by Application USD Million (2021-2026)
  • Table 194. South America Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 195. South America Contrast Agents, by End-User USD Million (2021-2026)
  • Table 196. South America Contrast Agents, by Modality USD Million (2021-2026)
  • Table 197. Brazil Contrast Agents, by Type USD Million (2021-2026)
  • Table 198. Brazil Contrast Agents, by Application USD Million (2021-2026)
  • Table 199. Brazil Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 200. Brazil Contrast Agents, by End-User USD Million (2021-2026)
  • Table 201. Brazil Contrast Agents, by Modality USD Million (2021-2026)
  • Table 202. Argentina Contrast Agents, by Type USD Million (2021-2026)
  • Table 203. Argentina Contrast Agents, by Application USD Million (2021-2026)
  • Table 204. Argentina Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 205. Argentina Contrast Agents, by End-User USD Million (2021-2026)
  • Table 206. Argentina Contrast Agents, by Modality USD Million (2021-2026)
  • Table 207. Rest of South America Contrast Agents, by Type USD Million (2021-2026)
  • Table 208. Rest of South America Contrast Agents, by Application USD Million (2021-2026)
  • Table 209. Rest of South America Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 210. Rest of South America Contrast Agents, by End-User USD Million (2021-2026)
  • Table 211. Rest of South America Contrast Agents, by Modality USD Million (2021-2026)
  • Table 212. Asia Pacific Contrast Agents, by Country USD Million (2021-2026)
  • Table 213. Asia Pacific Contrast Agents, by Type USD Million (2021-2026)
  • Table 214. Asia Pacific Contrast Agents, by Application USD Million (2021-2026)
  • Table 215. Asia Pacific Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 216. Asia Pacific Contrast Agents, by End-User USD Million (2021-2026)
  • Table 217. Asia Pacific Contrast Agents, by Modality USD Million (2021-2026)
  • Table 218. China Contrast Agents, by Type USD Million (2021-2026)
  • Table 219. China Contrast Agents, by Application USD Million (2021-2026)
  • Table 220. China Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 221. China Contrast Agents, by End-User USD Million (2021-2026)
  • Table 222. China Contrast Agents, by Modality USD Million (2021-2026)
  • Table 223. Japan Contrast Agents, by Type USD Million (2021-2026)
  • Table 224. Japan Contrast Agents, by Application USD Million (2021-2026)
  • Table 225. Japan Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 226. Japan Contrast Agents, by End-User USD Million (2021-2026)
  • Table 227. Japan Contrast Agents, by Modality USD Million (2021-2026)
  • Table 228. India Contrast Agents, by Type USD Million (2021-2026)
  • Table 229. India Contrast Agents, by Application USD Million (2021-2026)
  • Table 230. India Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 231. India Contrast Agents, by End-User USD Million (2021-2026)
  • Table 232. India Contrast Agents, by Modality USD Million (2021-2026)
  • Table 233. South Korea Contrast Agents, by Type USD Million (2021-2026)
  • Table 234. South Korea Contrast Agents, by Application USD Million (2021-2026)
  • Table 235. South Korea Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 236. South Korea Contrast Agents, by End-User USD Million (2021-2026)
  • Table 237. South Korea Contrast Agents, by Modality USD Million (2021-2026)
  • Table 238. Taiwan Contrast Agents, by Type USD Million (2021-2026)
  • Table 239. Taiwan Contrast Agents, by Application USD Million (2021-2026)
  • Table 240. Taiwan Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 241. Taiwan Contrast Agents, by End-User USD Million (2021-2026)
  • Table 242. Taiwan Contrast Agents, by Modality USD Million (2021-2026)
  • Table 243. Australia Contrast Agents, by Type USD Million (2021-2026)
  • Table 244. Australia Contrast Agents, by Application USD Million (2021-2026)
  • Table 245. Australia Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 246. Australia Contrast Agents, by End-User USD Million (2021-2026)
  • Table 247. Australia Contrast Agents, by Modality USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Contrast Agents, by Type USD Million (2021-2026)
  • Table 249. Rest of Asia-Pacific Contrast Agents, by Application USD Million (2021-2026)
  • Table 250. Rest of Asia-Pacific Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 251. Rest of Asia-Pacific Contrast Agents, by End-User USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Contrast Agents, by Modality USD Million (2021-2026)
  • Table 253. Europe Contrast Agents, by Country USD Million (2021-2026)
  • Table 254. Europe Contrast Agents, by Type USD Million (2021-2026)
  • Table 255. Europe Contrast Agents, by Application USD Million (2021-2026)
  • Table 256. Europe Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 257. Europe Contrast Agents, by End-User USD Million (2021-2026)
  • Table 258. Europe Contrast Agents, by Modality USD Million (2021-2026)
  • Table 259. Germany Contrast Agents, by Type USD Million (2021-2026)
  • Table 260. Germany Contrast Agents, by Application USD Million (2021-2026)
  • Table 261. Germany Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 262. Germany Contrast Agents, by End-User USD Million (2021-2026)
  • Table 263. Germany Contrast Agents, by Modality USD Million (2021-2026)
  • Table 264. France Contrast Agents, by Type USD Million (2021-2026)
  • Table 265. France Contrast Agents, by Application USD Million (2021-2026)
  • Table 266. France Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 267. France Contrast Agents, by End-User USD Million (2021-2026)
  • Table 268. France Contrast Agents, by Modality USD Million (2021-2026)
  • Table 269. Italy Contrast Agents, by Type USD Million (2021-2026)
  • Table 270. Italy Contrast Agents, by Application USD Million (2021-2026)
  • Table 271. Italy Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 272. Italy Contrast Agents, by End-User USD Million (2021-2026)
  • Table 273. Italy Contrast Agents, by Modality USD Million (2021-2026)
  • Table 274. United Kingdom Contrast Agents, by Type USD Million (2021-2026)
  • Table 275. United Kingdom Contrast Agents, by Application USD Million (2021-2026)
  • Table 276. United Kingdom Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 277. United Kingdom Contrast Agents, by End-User USD Million (2021-2026)
  • Table 278. United Kingdom Contrast Agents, by Modality USD Million (2021-2026)
  • Table 279. Netherlands Contrast Agents, by Type USD Million (2021-2026)
  • Table 280. Netherlands Contrast Agents, by Application USD Million (2021-2026)
  • Table 281. Netherlands Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 282. Netherlands Contrast Agents, by End-User USD Million (2021-2026)
  • Table 283. Netherlands Contrast Agents, by Modality USD Million (2021-2026)
  • Table 284. Rest of Europe Contrast Agents, by Type USD Million (2021-2026)
  • Table 285. Rest of Europe Contrast Agents, by Application USD Million (2021-2026)
  • Table 286. Rest of Europe Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 287. Rest of Europe Contrast Agents, by End-User USD Million (2021-2026)
  • Table 288. Rest of Europe Contrast Agents, by Modality USD Million (2021-2026)
  • Table 289. MEA Contrast Agents, by Country USD Million (2021-2026)
  • Table 290. MEA Contrast Agents, by Type USD Million (2021-2026)
  • Table 291. MEA Contrast Agents, by Application USD Million (2021-2026)
  • Table 292. MEA Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 293. MEA Contrast Agents, by End-User USD Million (2021-2026)
  • Table 294. MEA Contrast Agents, by Modality USD Million (2021-2026)
  • Table 295. Middle East Contrast Agents, by Type USD Million (2021-2026)
  • Table 296. Middle East Contrast Agents, by Application USD Million (2021-2026)
  • Table 297. Middle East Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 298. Middle East Contrast Agents, by End-User USD Million (2021-2026)
  • Table 299. Middle East Contrast Agents, by Modality USD Million (2021-2026)
  • Table 300. Africa Contrast Agents, by Type USD Million (2021-2026)
  • Table 301. Africa Contrast Agents, by Application USD Million (2021-2026)
  • Table 302. Africa Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 303. Africa Contrast Agents, by End-User USD Million (2021-2026)
  • Table 304. Africa Contrast Agents, by Modality USD Million (2021-2026)
  • Table 305. North America Contrast Agents, by Country USD Million (2021-2026)
  • Table 306. North America Contrast Agents, by Type USD Million (2021-2026)
  • Table 307. North America Contrast Agents, by Application USD Million (2021-2026)
  • Table 308. North America Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 309. North America Contrast Agents, by End-User USD Million (2021-2026)
  • Table 310. North America Contrast Agents, by Modality USD Million (2021-2026)
  • Table 311. United States Contrast Agents, by Type USD Million (2021-2026)
  • Table 312. United States Contrast Agents, by Application USD Million (2021-2026)
  • Table 313. United States Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 314. United States Contrast Agents, by End-User USD Million (2021-2026)
  • Table 315. United States Contrast Agents, by Modality USD Million (2021-2026)
  • Table 316. Canada Contrast Agents, by Type USD Million (2021-2026)
  • Table 317. Canada Contrast Agents, by Application USD Million (2021-2026)
  • Table 318. Canada Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 319. Canada Contrast Agents, by End-User USD Million (2021-2026)
  • Table 320. Canada Contrast Agents, by Modality USD Million (2021-2026)
  • Table 321. Mexico Contrast Agents, by Type USD Million (2021-2026)
  • Table 322. Mexico Contrast Agents, by Application USD Million (2021-2026)
  • Table 323. Mexico Contrast Agents, by Route of Administration USD Million (2021-2026)
  • Table 324. Mexico Contrast Agents, by End-User USD Million (2021-2026)
  • Table 325. Mexico Contrast Agents, by Modality USD Million (2021-2026)
  • Table 326. Contrast Agents: by Type(USD/Units)
  • Table 327. Research Programs/Design for This Report
  • Table 328. Key Data Information from Secondary Sources
  • Table 329. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Contrast Agents: by Type USD Million (2015-2020)
  • Figure 5. Global Contrast Agents: by Application USD Million (2015-2020)
  • Figure 6. Global Contrast Agents: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Contrast Agents: by End-User USD Million (2015-2020)
  • Figure 8. Global Contrast Agents: by Modality USD Million (2015-2020)
  • Figure 9. South America Contrast Agents Share (%), by Country
  • Figure 10. Asia Pacific Contrast Agents Share (%), by Country
  • Figure 11. Europe Contrast Agents Share (%), by Country
  • Figure 12. MEA Contrast Agents Share (%), by Country
  • Figure 13. North America Contrast Agents Share (%), by Country
  • Figure 14. Global Contrast Agents: by Type USD/Units (2015-2020)
  • Figure 15. Global Contrast Agents share by Players 2020 (%)
  • Figure 16. Global Contrast Agents share by Players (Top 3) 2020(%)
  • Figure 17. Global Contrast Agents share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. E Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 20. E Healthcare (United States) Revenue: by Geography 2020
  • Figure 21. Bracco Imaging SPA (Italy) Revenue, Net Income and Gross profit
  • Figure 22. Bracco Imaging SPA (Italy) Revenue: by Geography 2020
  • Figure 23. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 25. Guerbet (France) Revenue, Net Income and Gross profit
  • Figure 26. Guerbet (France) Revenue: by Geography 2020
  • Figure 27. Lantheus Medical Imaging, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Lantheus Medical Imaging, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Unijules Life Sciences (India) Revenue, Net Income and Gross profit
  • Figure 30. Unijules Life Sciences (India) Revenue: by Geography 2020
  • Figure 31. J.B. Chemicals and Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. J.B. Chemicals and Pharmaceuticals Ltd. (India) Revenue: by Geography 2020
  • Figure 33. SANOCHEMIA Pharmazeutika GmbH (Austria) Revenue, Net Income and Gross profit
  • Figure 34. SANOCHEMIA Pharmazeutika GmbH (Austria) Revenue: by Geography 2020
  • Figure 35. Taejoon Pharm (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. Taejoon Pharm (South Korea) Revenue: by Geography 2020
  • Figure 37. Jodas Expoim (India) Revenue, Net Income and Gross profit
  • Figure 38. Jodas Expoim (India) Revenue: by Geography 2020
  • Figure 39. Nano Therapeutics Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 40. Nano Therapeutics Pvt. Ltd. (India) Revenue: by Geography 2020
  • Figure 41. Kiran X-ray (India) Revenue, Net Income and Gross profit
  • Figure 42. Kiran X-ray (India) Revenue: by Geography 2020
  • Figure 43. IMax Diagnostic Imaging Limited (Ireland) Revenue, Net Income and Gross profit
  • Figure 44. IMax Diagnostic Imaging Limited (Ireland) Revenue: by Geography 2020
  • Figure 45. K DIAM EXIM (India) Revenue, Net Income and Gross profit
  • Figure 46. K DIAM EXIM (India) Revenue: by Geography 2020
  • Figure 47. Global Contrast Agents: by Type USD Million (2021-2026)
  • Figure 48. Global Contrast Agents: by Application USD Million (2021-2026)
  • Figure 49. Global Contrast Agents: by Route of Administration USD Million (2021-2026)
  • Figure 50. Global Contrast Agents: by End-User USD Million (2021-2026)
  • Figure 51. Global Contrast Agents: by Modality USD Million (2021-2026)
  • Figure 52. South America Contrast Agents Share (%), by Country
  • Figure 53. Asia Pacific Contrast Agents Share (%), by Country
  • Figure 54. Europe Contrast Agents Share (%), by Country
  • Figure 55. MEA Contrast Agents Share (%), by Country
  • Figure 56. North America Contrast Agents Share (%), by Country
  • Figure 57. Global Contrast Agents: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • E Healthcare (United States)
  • Bracco Imaging SPA (Italy)
  • Bayer AG (Germany)
  • Guerbet (France)
  • Lantheus Medical Imaging, Inc. (United States)
  • Unijules Life Sciences (India)
  • J.B. Chemicals and Pharmaceuticals Ltd. (India)
  • SANOCHEMIA Pharmazeutika GmbH (Austria)
  • Taejoon Pharm (South Korea)
  • Jodas Expoim (India)
  • Nano Therapeutics Pvt. Ltd. (India)
  • Kiran X-ray (India)
  • iMax Diagnostic Imaging Limited (Ireland)
  • K DIAM EXIM (India)
Additional players considered in the study are as follows:
Congruent Pharmachem Private Limited (India) , Stanex Drugs & Chemical Pvt. Ltd. (India) , Beijing Beilu Pharmaceutical Co., Ltd. (China) , Subhra Pharma Pvt. Ltd. (India)
Select User Access Type

Key Highlights of Report


Sep 2021 203 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Contrast Agents Quantitative research analysis
Global Contrast Agents Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Contrast Agents Report?

Have a Query? Click Here

Other Related Reports

Skin Adhesives Comprehensive Study by Application (Ophthalmic Surgery, ENT Surgery, Dental Surgery, General Surgery, Plastic Surgery, Gynaecology, Gastroenterology, Orthopaedic, Surgical oncology, Ot...
$ 3650
Left Ventricular Dysfunction Drug Comprehensive Study by Type (BAY-1142524, CAP-1002, Carvedilol CR, CTX-101, Omecamtiv Mecarbil, Others), Application (Hospital, Clinic, Others), Drug Type (Prescript...
$ 3450
Animal Parasiticides - Comprehensive Study by Type (Endoparasiticides (Oral, Injectables), Ectoparasiticides (Sprays, Pour On, Spot On), Endectocides), Application (Agriculture, Horticulture), Form (...
$ 3350
Guillain-Barre Syndrome Drugs Comprehensive Study by Type (Coversin, Immune Globulin, Others), Application (Clinic, Hospital, Others), Forms (Tablets, Injection), Distribution Channel (Hospital Pharm...
$ 3350
Burkholderia Pseudomallei Infections Drug Comprehensive Study by Type (Cholinesterase inhibitors, Memantine), Application (Reduce Fever, Improves Breathing Conditions, Others), Distribution Channel (...
$ 3650
Pharmacovigilance Software Comprehensive Study by End users (Pharma and Biotech Companies, Contract Research Organizations, Business Process Outsourcing Firms, Other), Software (Oracle Argus Safety, ...
$ 4000